Opioid crisis in the US - Business & addiction (2/2) | DW Documentary

Key Concepts

• Fentanyl & Opioid Crisis: The central focus is the rise of fentanyl, its aggressive marketing, and its devastating impact on the US, transitioning from a cancer pain medication to a major driver of the opioid epidemic.
• Incis Therapeutics & Alec Burlov: The story centers on Incis, a pharmaceutical company, and its aggressive sales tactics under Alec Burlov to push the fentanyl spray, Subsist.
• Pill Mills & George Brothers: The role of unregulated pain clinics ("pill mills") in Florida, particularly those run by the George brothers, in fueling the opioid crisis.
• RICO Act & Criminal Prosecution: The use of the Racketeer Influenced and Corrupt Organizations (RICO) Act to prosecute Incis and its executives.
• Whistleblowers & Investigative Techniques: The crucial role of whistleblowers and investigative methods (undercover operations, wiretaps) in uncovering the fraudulent practices of Incis.
• Cartel Involvement: The shift in fentanyl supply from pharmaceutical companies to Mexican cartels, and the cartels’ adaptation to the US market.
• Insurance Fraud & Reimbursement Schemes: The elaborate scheme by Incis to fraudulently obtain insurance reimbursement for Subsist, misrepresenting its use.
• Corporate Accountability & Sackler Family: The lack of significant criminal accountability for pharmaceutical executives, exemplified by the Sackler family’s limited consequences despite their role in the opioid crisis.

The Rise and Fall of Incis Therapeutics: A Deep Dive into the Fentanyl Crisis

I. The Emergence of Fentanyl and the Competitive Landscape

The video details the emergence of fentanyl as a lucrative drug for pharmaceutical companies following the success of Purdue Pharma’s OxyContin. Fentanyl, a highly potent opioid (50 times stronger than heroin), was initially developed as a “miracle spray” for breakthrough cancer pain. However, the competitive pharmaceutical market, coupled with the desire for a successful IPO, led Incis Therapeutics to aggressively market the drug, despite its addictive potential. John Kapoor, the owner of Incis, was driven by the potential for massive profits, recognizing the $2 billion annual revenue generated by Purdue Pharma.

II. Aggressive Sales Tactics and the IPO

To boost sales, Incis hired Alec Burlov, described as an “aggressive” individual. Burlov implemented a strategy focused on rapid growth and a successful initial public offering (IPO). In 2013, Incis went public, achieving a stock value exceeding $1 billion. This success was fueled by aggressive sales tactics, including a controversial “speaker program” where doctors were incentivized to prescribe the drug, often without delivering any actual presentations. A key element of this strategy involved hiring women, many with backgrounds as exotic dancers, to build relationships with doctors and influence their prescribing habits. As one interviewee stated, “I see a bunch of these young girls with some of the executives in a jacuzzi and I just thought, 'These girls don't know what they're getting themselves into.'” Mia Guzman, a former sales rep, blew the whistle on these practices, stating, “Our goal was to get money in the physician's pocket so that we could directly influence them to use more of the medication.”

III. The Dark Side: Pill Mills and the Florida Epidemic

The video highlights the parallel rise of “pill mills” in Florida, characterized by lax regulations and a free-for-all environment. Clinics operated with minimal medical oversight, often hiring doctors solely for their prescription pads. The George brothers, identified as the most prolific distributors, sourced oxycodone and fentanyl from wholesalers and supplied these clinics. The situation in Florida was so dire that there were more pain clinics than McDonald’s restaurants. One interviewee described the scene: “You would have clinics where someone would hire doctors, but really they weren't hiring doctors. They were hiring doctors prescription pads.” The environment was chaotic and dangerous, with doctors carrying guns and drug deals occurring openly in parking lots.

IV. The Cartel Connection and Synthetic Fentanyl

As regulations tightened in the US, Mexican cartels recognized the profitability of the fentanyl market. They began sourcing fentanyl precursors and manufacturing the drug synthetically, bypassing the need for poppy cultivation. Luis, a former cartel member, recounts how the cartels saw the opportunity: “They figured out that Americans love pills. We love pills.” The cartels quickly adapted, counterfeiting pills and distributing them through various channels, including the internet and social media. The video emphasizes the danger of these counterfeit pills, stating, “Any pill anybody buys that is not coming from a pharmacy, I’d be willing to bet a lot of money that has got fentanyl in it.”

V. Investigative Efforts and Legal Battles

The investigation into Incis involved a multi-pronged approach, including whistleblowers, undercover operations, and wiretaps. Nathaniel Jagger played a key role, relying on evidence gathered from whistleblower recordings. Two sales reps went undercover in Arizona, capturing conversations where company officials discussed strategies for increasing fentanyl prescriptions, even suggesting its use for depression. The US Attorney’s Office utilized the RICO Act to prosecute Incis and its executives. The video details the discovery of $4.5 million in cash at the home of Chris George’s mother, highlighting the scale of the operation.

VI. Insurance Fraud and the Reimbursement Scheme

A critical aspect of Incis’s fraudulent scheme involved manipulating insurance companies to cover the cost of Subsist. The company established a reimbursement center staffed with operators who falsely presented the drug as being used for breakthrough cancer pain, even when it wasn’t. Patricia Nixon, a former call center operator, described the practice: “We had to lie to the insurance company…It was a word game.” This fraudulent activity allowed Incis to generate significant revenue.

VII. The Tragic Case of Sarah Fuller and the Lack of Accountability

The story of Sarah Fuller, a patient who died after being prescribed fentanyl despite not having cancer, exemplifies the devastating consequences of Incis’s actions. Her family was never informed that the drug was an opioid or that it carried a high risk of addiction. The video highlights the lack of accountability for pharmaceutical executives, noting that while Purdue Pharma pleaded guilty to felonies, no one from the Sackler family faced criminal charges. The narrator states, “Many of us think that’s not right.”

VIII. The Cycle of Profit and the Ongoing Crisis

The video concludes by drawing a broader connection between the opioid crisis and the capitalist drive for profit. It argues that corporations are often willing to prioritize profits over public health, and that this dynamic extends beyond pharmaceuticals to other industries like sugar, coffee, and social media. The final scenes depict the ongoing struggle against fentanyl, with law enforcement seizing millions of pills and the cartels continuing to adapt and innovate. The video ends with a powerful statement: “There’s only one thing left to do, and that’s to do justice.”

Technical Terms & Concepts:

• RICO Act (Racketeer Influenced and Corrupt Organizations Act): A US federal law used to prosecute organized crime, including financial crimes and fraud.
• Titration: Gradually increasing the dosage of a drug.
• Subsist: The brand name of the fentanyl spray produced by Incis Therapeutics.
• Pill Mill: An unregulated pain clinic that indiscriminately prescribes opioids.
• IPO (Initial Public Offering): The process of offering shares of a private company to the public for the first time.
• Breakthrough Cancer Pain: Sudden, severe pain experienced by cancer patients despite ongoing pain management.

This summary aims to provide a detailed and specific account of the video’s content, preserving the original language and technical precision. It focuses on actionable insights and specific details rather than broad generalizations.